

Table S2: The comparison of the treatment protocols between MS4A3 low-expression cases and MS4A3 high-expression cases in the TCGA AML cohort.

Regimen	High MS4A3 expression		Low MS4A3 expression		P-value
	Count	Proportion	Count	Proportion	
7+3 regimen	32	54.24%	34	44.74%	0.27
7+3+3 regimen	15	25.42%	23	30.26%	0.53
Decitabine	2	3.39%	10	13.16%	0.57
Revlimid	2	3.39%	6	7.89%	0.65
no treatment	4	6.78%	1	1.32%	-
others	4	6.78%	2	2.63%	-

P-values were calculated by using the chi-square test.

Table S3: The comparison of the treatment protocols between CD96 low-expression cases and CD96 high-expression cases in the TCGA AML cohort.

Regimen	High CD96 expression		Low CD96 expression		P-value
	Count	Proportion	Count	Proportion	
7+3 regimen	18	48.65%	48	48.98%	0.97
7+3+3 regimen	14	37.84%	24	24.49%	0.12
Decitabine	1	2.70%	11	11.22%	0.23
Revlimid	3	8.11%	5	5.10%	0.79
no treatment	0	0.00%	5	5.10%	-
others	1	2.70%	5	5.10%	-

P-values were calculated by using the chi-square test.

Table S4: The comparison of the treatment protocols between LTK low-expression cases and LTK high-expression cases in the TCGA AML cohort.

Regimen	High LTK expression		Low LTK expression		P-value
	Count	Proportion	Count	Proportion	
7+3 regimen	35	51.47%	31	46.27%	0.54
7+3+3 regimen	22	32.35%	16	23.88%	0.27
Decitabine	4	5.88%	8	11.94%	0.44
Revlimid	1	1.47%	7	10.45%	0.07
no treatment	3	4.41%	2	2.99%	-
others	3	4.41%	3	4.48%	-

P-values were calculated by using the chi-square test.